Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Has Results Drug: lasmiditan 200 mg|Drug: Sumatriptan|Drug: matching placebo Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Diastolic Blood Pressure|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Pulse Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Temperature|Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Respiratory Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Heart Rate|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) PR Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QRS Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcB - Bazett's Correction Formula|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: QTcF - Fridericia's Correction Formula|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) QT Duration|Pharmacodynamics- Change From Pre-dose to 24 Hours in ECGs: Summary (Mean) RR Duration|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Pharmacokinetics - Cmax|Pharmacokinetics - AUC0-t|Pharmacokinetics - Tmax All Phase 1 42 Industry Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science 16885|col mig-118|h8h-cd-lahi April 13, 2017